{"id":83651,"date":"2020-04-18T01:39:56","date_gmt":"2020-04-18T04:39:56","guid":{"rendered":"https:\/\/megalabs.global\/por\/?p=83651"},"modified":"2020-04-23T18:24:50","modified_gmt":"2020-04-23T21:24:50","slug":"lopinavir-ritonavir","status":"publish","type":"post","link":"https:\/\/megalabs.global\/por\/lopinavir-ritonavir\/","title":{"rendered":"Lopinavir\/Ritonavir"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”100″ gutter_size=”3″ shift_y=”0″ row_height_use_pixel=””][vc_column column_width_use_pixel=”yes” gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ medium_width=”0″ zoom_width=”0″ zoom_height=”0″ column_width_pixel=”800″][vc_column_text]El Lopinavir\/Ritonavir es un inhibidor de la proteasa del VIH-1 indicado en combinaci\u00f3n con otros agentes antirretrovirales para el tratamiento de la infecci\u00f3n por VIH-1 en adultos y pacientes pedi\u00e1tricos. Ha sido aprobado por la FDA en 2006. (6)<\/p>\n

Dosis y administraci\u00f3n propuestas para COVID-19 (1)<\/strong><\/p>\n

Adultos<\/strong><\/em>
\n\u2022 Lopinavir\/Ritonavir 200 mg\/100 mg comprimidos: la dosis es 400\/100mg (2 comprimidos) cada 12 horas v\u00eda oral. La duraci\u00f3n ser\u00e1 individualizada, pudiendo utilizarse de gu\u00eda para la retirada la desa-parici\u00f3n de la fiebre, y la duraci\u00f3n m\u00e1xima ser\u00e1 de 14 d\u00edas.
\n\u2022 Lopinavir\/Ritonavir 80\/20 mg\/ml soluci\u00f3n oral: la dosis es 400\/100mg (5 ml) cada 12 horas v\u00eda ad-ministraci\u00f3n por sonda. La soluci\u00f3n debe reservarse para pacientes intubados en cuidados inten-sivos y para la poblaci\u00f3n pedi\u00e1trica que no sea subsidiaria de tratamiento con los comprimidos, ya sea porque la dosis es inapropiada o por las dificultades para tragar los mismos.<\/p>\n

Pedi\u00e1trico<\/strong><\/em>
\n\u2022 Pacientes pedi\u00e1tricos desde los 14 d\u00edas hasta los 6 meses: 16\/4 mg\/kg\/dosis (corresponde a 0,2 mL\/kg), 2 veces al d\u00eda o 300\/75 mg\/m2 dosis (corresponde a 3,75 mL\/m2), 2 veces al d\u00eda.
\n\u2022 Pacientes pedi\u00e1tricos desde los 6 meses hasta los 18 a\u00f1os:
\no 7 a 15 kg 12\/3 mg\/kg\/dosis, 2 veces\/d\u00eda.<\/p>\n

o 15-40 kg 10\/2.5 mg\/kg\/dosis, 2 veces\/d\u00eda.<\/p>\n

o >40 kg: 400 \/100 mg (200 mg\/50 mg por c\u00e1psula), dos c\u00e1psulas (o 5 mL de la solu-ci\u00f3n), 2 veces\/d\u00eda.<\/p>\n

Precauciones y advertencias (2)<\/strong>
\n\u2022 Toxicidad en neonatos prematuros: no debe usarse en neonatos prematuros en el per\u00edodo pos-natal inmediato debido a posibles toxicidades. No se ha establecido una dosis segura y efectiva de soluci\u00f3n oral en esta poblaci\u00f3n de pacientes.
\n\u2022 Pancreatitis
\n\u2022 Hepatotoxicidad: monitorer la funci\u00f3n hep\u00e1tica antes y durante la terapia, especialmente en pa-cientes con enfermedad hep\u00e1tica subyacente, incluyendo hepatitis B y hepatitis C, o elevaciones marcadas de transaminasas.
\n\u2022 Se han informado casos de prolongaci\u00f3n del intervalo QT y casos aislados de torsade de pointes.
\n\u2022 La prolongaci\u00f3n del intervalo PR puede ocurrir en algunos pacientes. Usar con precauci\u00f3n en pa-cientes con enfermedad del sistema de conducci\u00f3n preexistente, cardiopat\u00eda isqu\u00e9mica, miocar-diopat\u00eda, cardiopat\u00eda estructural subyacente o cuando se administra con otros medicamentos que pueden prolongar el intervalo PR.
\n\u2022 Los pacientes pueden desarrollar un nuevo inicio o exacerbaciones de diabetes mellitus, hiperglu-cemia, s\u00edndrome de reconstituci\u00f3n inmune, redistribuci\u00f3n\/acumulaci\u00f3n de grasa corporal.
\n\u2022 Elevaciones totales de colesterol y triglic\u00e9ridos. Monitorear antes de la terapia y peri\u00f3dicamente despu\u00e9s.
\n\u2022 Hemofilia: puede producirse un sangrado espont\u00e1neo y puede ser necesario factor VIII adicional.<\/p>\n

Eventos adversos (2)<\/strong>
\nFrecuentes: diarrea, n\u00e1useas, v\u00f3mitos, hipertrigliceridemia e hipercolesterolemia. Infrecuentes: pancreatitis, prolongaci\u00f3n del segmento QT del electrocardiograma.
\nSu uso puede implicar serios eventos adversos a nivel de p\u00e1ncreas e h\u00edgado, observ\u00e1ndose casos de pancreatitis y hepatotoxicidad, llegando a incluir resultados fatales.<\/p>\n

Estudios cl\u00ednicos con COVID-19<\/strong>
\n\u2022 Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy). (3)[\/vc_column_text][vc_single_image media=”83654″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”664″][vc_column_text]\u2022 Comparison of Lopinavir\/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Dis-ease (COVID-19). (4)[\/vc_column_text][vc_single_image media=”83655″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”713″][vc_column_text]\u2022 Lopinavir\/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment. (5)[\/vc_column_text][vc_single_image media=”83656″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”711″][vc_column_text]\u2022 COVID-19 Ring-based Prevention Trial With Lopinavir\/Ritonavir (CORIPREV-LR). (6)[\/vc_column_text][vc_single_image media=”83657″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”710″][vc_column_text]\u2022 Evaluating and Comparing the Safety and Efficiency of ASC09\/Ritonavir and Lopinavir\/Ritonavir for Novel Coronavirus Infection. (7)[\/vc_column_text][vc_single_image media=”83658″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”712″][vc_column_text]\u2022 Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe). (8)[\/vc_column_text][vc_single_image media=”83659″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”716″][vc_column_text]\u2022 The Clinical Study of Carrimycin on Treatment Patients With COVID-19. (9)[\/vc_column_text][vc_single_image media=”83660″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”713″][vc_column_text]Link a informaci\u00f3n del producto de FDA:
\nwww.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021251s058,021906s053lbl.pdf<\/a>.<\/p>\n

(1) Tratamientos disponibles para el manejo de la infecci\u00f3n respiratoria por SARS-CoV-2. AEMPS2020.
\nAvailable from: https:\/\/www.aemps.gob.es\/la-aemps\/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119\/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2\/<\/a>.<\/p>\n

(2) Inserto Kaletra Food and Drug Administration2019.
\nAvailable from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021251s058,021906s053lbl.pdf<\/a>.<\/p>\n

(3) Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy). 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315948<\/a>.<\/p>\n

(4) Comparison of Lopinavir\/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Dis-ease (COVID-19) 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04307693<\/a>.<\/p>\n

(5) Lopinavir\/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688<\/a>.<\/p>\n

(6) COVID-19 Ring-based Prevention Trial With Lopinavir\/Ritonavir (CORIPREV-LR) 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321174<\/a>.<\/p>\n

(7) Evaluating and Comparing the Safety and Efficiency of ASC09\/Ritonavir and Lopinavir\/Ritonavir for Novel Coronavirus Infection 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261907<\/a>.<\/p>\n

(8) Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04295551<\/a>.<\/p>\n

(9) The Clinical Study of Carrimycin on Treatment Patients With COVID-19 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04286503<\/a>.[\/vc_column_text][vc_empty_space empty_h=”3″][vc_row_inner row_inner_height_percent=”0″ overlay_alpha=”50″ gutter_size=”3″ border_color=”color-877404″ border_style=”solid” shift_y=”0″ z_index=”0″ css=”.vc_custom_1572995729128{border-top-width: 1px !important;border-bottom-width: 1px !important;padding-top: 18px !important;padding-bottom: 18px !important;}” el_class=”descarga-pdf” limit_content=””][vc_column_inner width=”1\/1″][vc_icon position=”left” icon_image=”82110″ icon_color=”color-877404″ media_size=”42″ text_font=”font-195522″ text_weight=”700″ linked_title=”yes” title=”Descargar Documento” link=”url:%2Fwp-content%2Fuploads%2F2020%2F04%2FConexi%C3%B3n_Lopinavir-Ritonavir.pdf|title:Conexi%C3%B3n_Lopinavir%20Ritonavir|target:%20_blank|”]Conexi\u00f3n_Lopinavir Ritonavir[\/vc_icon][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Comprimidos<\/p>\n","protected":false},"author":1,"featured_media":83821,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[94],"tags":[],"class_list":["post-83651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farmacos"],"_links":{"self":[{"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/posts\/83651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/comments?post=83651"}],"version-history":[{"count":0,"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/posts\/83651\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/media\/83821"}],"wp:attachment":[{"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/media?parent=83651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/categories?post=83651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/megalabs.global\/por\/wp-json\/wp\/v2\/tags?post=83651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}